Based on the level of F2-isoprostanes, the effect of Erzhi Tiangui prescription on the outcome of IVF treatment in patients with DOR and the syndrome analysis of patients with DOR

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900021553

Enrollment

Unknown

Registered

2019-02-27

Start date

2019-02-26

Completion date

Unknown

Last updated

2019-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diminished Ovarian Reserve

Interventions

Experimental group:Erzhi Tiangui prescription

Control group:Placebo

Eligibility

Sex/Gender

Female

Age

25 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. High-risk factors for the decline of ovarian reserve function: (1) Ovarian lesions: such as endometriosis, ovarian tuberculosis, severe pelvic and periovarian inflammation and adhesion, Chlamydia infection, cytomegalovirus infection, ovarian dysplasia, single ovary, etc.; (2) History of ovarian and fallopian tube surgery: such as one-sided ovariectomy, ovarian cyst exfoliation, etc.; (3) Exemption; Epidemiological factors: such as anti-ovarian antibody, anti-zona pellucida antibody, anti-Gn receptor antibody, etc.; (4) Environmental and life factors: long-term exposure to organic solvents, pesticides, heavy metals and other harmful substances, physical bliss, smoking and alcoholism and other bad habits. 2. Past history of ovarian hyporesponsiveness: The standard ovulation stimulation program was used: (1) The number of mature follicles (diameter > 14mm) on the day of injection was less than 3-5 or the number of eggs obtained was less than 3-5; (2) The serum E2 peak was less than 300-500 pg/ml; the daily dose of Gn was more than 300 IU or the total dose was more than 3000IU (25-44); 3. Abnormal indicators of ovarian reserve function: (1) Bilateral AFC 10IU/L; (3) FSH/LH > 3.6; (4) basal E2 level > 80pg/ml.

Exclusion criteria

Exclusion criteria: 1. Complicated with other endocrine diseases, such as thyroid dysfunction, hyperprolactinemia, polycystic ovary syndrome, diabetes and so on; 2. Uterine malformations or other reproductive organ malformations, uterine organic lesions, hydrosalpinx, ovarian space-occupying lesions; 3. Severe oligozoospermia, weakness and teratozoospermia in males; 4. Combined use of other drugs to improve ovarian reserve function such as growth hormone and traditional Chinese medicine.

Design outcomes

Primary

Measure	Time frame
F2-isoprostanes;	—

Countries

China

Contacts

Public ContactLv Run

Shandong University of Traditional Chinese Medicine

18364165901@163.com+86 18364165901

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026